Sutter Raoul, De Marchis Gian Marco, Semmlack Saskia, Fuhr Peter, Rüegg Stephan, Marsch Stephan, Ziai Wendy C, Kaplan Peter W
Department of Neurology, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Division of Neurosciences Critical Care, Department of Anesthesiology, Critical Care Medicine and Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
CNS Drugs. 2017 Jan;31(1):65-74. doi: 10.1007/s40263-016-0389-5.
The use of anesthetics has been linked to poor outcome in patients with status epilepticus (SE). This association, however, may be confounded, as anesthetics are mostly administered in patients with more severe SE and critical illnesses.
To minimize treatment-selection bias, we assessed the association between continuously administered intravenous anesthetic drugs (IVADs) and outcome in SE patients by a matched two-center study design.
This cohort study was performed at the Johns Hopkins Bayview Medical Center, Baltimore, MD, USA and the University Hospital Basel, Basel, Switzerland. All consecutive adult SE patients from 2005 to 2013 were included. Odds ratios (ORs) for death and unfavorable outcome (Glasgow Outcome Score [GOS] 1-3) associated with administration of IVADs were calculated. To account for confounding by known outcome determinants (age, level of consciousness, worst seizure type, acute/fatal etiology, mechanical ventilation, and SE duration), propensity score matching and coarsened exact matching were performed in addition to multivariable regression models.
Among 406 consecutive patients, 139 (34.2%) were treated with IVADs. Logistic regression analyses of the unmatched and matched cohorts revealed increased odds for death and unfavorable outcome in survivors who had received IVADs (unmatched: OR = 3.13, 95% confidence interval [CI] 1.47-6.60 and OR = 2.51, 95% CI 1.37-4.60; propensity score matched: OR = 3.29, 95% CI 1.35-8.05 and OR = 2.27, 95% CI 1.02-5.06; coarsened exact matched: OR = 2.19, 95% CI 1.27-3.78 and OR = 3.94, 95% CI 2.12-7.32).
The use of IVADs in SE is associated with death and unfavorable outcome in survivors independent of known confounders and using different statistical approaches. Randomized trials are needed to determine if these associations are biased by outcome predictors not yet identified and hence not accounted for in this study.
麻醉药物的使用与癫痫持续状态(SE)患者的不良预后相关。然而,这种关联可能存在混淆因素,因为麻醉药物大多用于病情更严重的SE患者和危重症患者。
为尽量减少治疗选择偏倚,我们通过一项匹配的两中心研究设计,评估了持续静脉注射麻醉药物(IVADs)与SE患者预后之间的关联。
本队列研究在美国马里兰州巴尔的摩市的约翰霍普金斯湾景医疗中心以及瑞士巴塞尔的巴塞尔大学医院进行。纳入了2005年至2013年期间所有连续的成年SE患者。计算与使用IVADs相关的死亡和不良预后(格拉斯哥预后评分[GOS] 1 - 3)的比值比(ORs)。为了考虑已知预后决定因素(年龄、意识水平、最严重的癫痫发作类型、急性/致命病因、机械通气和SE持续时间)造成的混杂影响,除多变量回归模型外,还进行了倾向评分匹配和精确匹配。
在406例连续患者中,139例(34.2%)接受了IVADs治疗。对未匹配和匹配队列的逻辑回归分析显示,接受IVADs治疗的幸存者死亡和不良预后的几率增加(未匹配:OR = 3.13,95%置信区间[CI] 1.47 - 6.60,OR = 2.51,95% CI 1.37 - 4.60;倾向评分匹配:OR = 3.29,95% CI 1.35 - 8.05,OR = 2.27,95% CI 1.02 - 5.06;精确匹配:OR = 2.19,95% CI 1.27 - 3.78,OR = 3.94,95% CI 2.12 - 7.32)。
在SE患者中使用IVADs与幸存者的死亡和不良预后相关,且独立于已知的混杂因素,并采用了不同的统计方法。需要进行随机试验来确定这些关联是否受到尚未识别的预后预测因素的偏倚影响,因此本研究未对此进行考虑。